Researchers have developed a vaccine called NXT-2 that targets pathogenic fungal infections. The vaccine is being tested to determine its effectiveness against several kinds of fungal infections.

In pre-clinical trials, NXT-2 has shown promise in fighting the three most common infections, which account for the majority of deadly cases. Current treatments often struggle to keep up as fungi develop resistance to medication.

Further information on the vaccine and its potential benefits is available, including its potential to protect against fungal infections without harming the gut's microbiome.